Semax, an ACTH(4-10) Analogue, Reduces Ischemic Damage and Promotes Neurological Recovery After Experimental Stroke
Kovalenko LP, Myasoedov NF, Sharonova IN, Seredenin SB
CNS Drug Reviews · Vol. 25(3) · pp. 287–301 · 2019
Review of Semax's neuroprotective and neuroregenerative properties in ischemic stroke models and clinical use. Documents significant reduction in infarct volume, improved neurological outcomes, and BDNF upregulation. Semax is approved in Russia for stroke treatment and cognitive enhancement.
Key Findings
Semax reduces ischemic infarct volume by 30–50% in animal stroke models
Upregulates BDNF, NGF, and VEGF expression in ischemic brain tissue
Approved in Russia for ischemic stroke treatment and cognitive disorders
Improves attention, memory, and executive function in clinical studies
Intranasal delivery achieves effective CNS concentrations with minimal systemic exposure
Methodology
Review of preclinical ischemia models combined with analysis of Russian clinical trial data. Includes pharmacokinetic studies of intranasal delivery.
Limitations
Most clinical data from Russian trials with limited international replication. Regulatory status varies by country.
Protocols Using This Research
Tags
Educational use only. Research summaries are provided for informational purposes. Always consult the original publication and a qualified healthcare provider before making clinical decisions.
Related Research
Semax Stimulates BDNF Expression in the Rat Brain and Exerts Neuroprotective Eff…
2006 · Moderate Evidence
Selank and Anxiety: Results of a Phase III Clinical Trial for Generalized Anxiet…
2010 · Strong Evidence
Selank and Short Peptides of the Tuftsin Family in the Regulation of Adaptive Be…
2016 · Moderate Evidence
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) Produces Robust Cognitive En…
2013 · Moderate Evidence
Build a protocol around this research
Our AI Advisor incorporates the latest research to build a personalized peptide protocol for your goals.
Start Assessment